A081801 / RLUN20119 / ALCHEMIST-IO (ACCIO) / Yuhchyau Chen
Basic Study Information
Purpose:
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy
for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that
has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab,
may help the body's immune system attack the cancer, and may interfere with the ability
of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed,
carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to
stop the growth of tumor cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy
may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small
cell lung cancer.
Location: University of Rochester
Lead Researcher (Principal Investigator)
Lead Researcher:
Yuhchyau Chen
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search